HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cannabidiol Patch With 14-Hour Delivery OK In UK, But Not Pain, Anxiety And Diabetes Claims

Executive Summary

UK advertising regulator says an ad catalog retailer claiming a CBD patch could reduce chronic pain, anxiety and diabetes violated advertising codes. The agency says claims including the product penetrated quickly through skin were medicinal and not approved by the UK or EU.

You may also be interested in...



Cannabidiol Safety In Question At US FDA? Exploding Market Suggests Not So Much

A report FDA submitted to Congress earlier in March on determining an enforcement discretion policy for CBD-containing non-drug products did little to indicate it is approaching a decision. It's likely that FDA officials are reasonably confident of CBD's safety in food and supplements because the agency has allowed the market to proliferate.

UK CBD Firms Given Deadline For EU Compliance

BREAKING NEWS: UK food regulator, FSA, has given CBD firms until the 31 March 2021 to submit valid novel food applications under new EU rules. FSA says it will not take products off shelves until then, but has also warned some consumers against taking CBD due to "potential adverse health effects."

FDA Warns 15 CBD Product Marketers For Violations, Cautions Consumers: CBD May Harm You

The agency announces that it cannot conclude cannabidiol is GRAS, potentially heading off GRAS notifications and making NDI notifications a likelier future for CBD use in the supplement sector if any “lawful pathway” is to be found. In addition to a barrage of warning letters to marketers of CBD products, the FDA issued a stark warning to consumers about potential hazards.

Related Content

Topics

UsernamePublicRestriction

Register

RS149813

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel